Under the 340B program, participating manufacturers must offer 340B pricing on their covered outpatient drugs by covered entities, as a condition of having those drugs federally payable under Medicare Part B and Medicaid. Critically, Congress…
BIO submitted these comments in response to the United States Patent and Trademark Office’s May 10, 2024, Notice of Proposed Rulemaking regarding Terminal Disclaimer Practice to Obviate Nonstatutory Double Patenting.
February 21, 2017: Coalition Budget Letter
March 9, 2017: James C. Greenwood Testimony on Farm Bill Rural Development & Energy Programs
October 19, 2017: BIO Letter to Congress on Biorefinery, Renewable Chemical, and Biobased Manufacturing Assistance Program
December 6, 2017: BIO, ASTA, USBC, BPIA and Humic Products Letter to Conaway on Biostimulants
February 6, 2018: IowaBio Farm Bill Energy Title Support Letter
March 6, 2018: National Farm Bill Energy Title Support Letter
April 12, 2018: Agriculture Energy Coalition Press Release on Farm Bill Energy Title Funding
April 17, 2018: Bio Nebraska Farm Bill Energy Title Support Letter
April 26, 2018: BIO, ASTA, USBC, BPIA and Humic Products Letter to Conaway on Biostimulants
June 12, 2018: Coalition Letter Farm Bill Ag Improvement Act
May 9, 2018: BIO, ASTA, USBC, BPIA and Humic Products to Roberts on Biostimulants
July 16, 2018: BIO Letter Farm Bill Conference Committee
August 13, 2018: Coalition Letter on Farm Bill Conference
August 24, 2018: National Ag Farm Bill Energy Title Letter
August 30, 2018: Agriculture Energy Coalition Letter on Farm Bill
October 9, 2018: BIO Oped on Farm Bill Energy Title in Biofuels Digest
October 15, 2018: Texas Energy Letter on Farm Bill Energy Title
October 18, 2018: Farm Bill Letter to Conference Committee
October 18, 2018: Farm Bill Letter to House/Senate Leadership
November 16, 2018: BIO Letter to Congresssional Leadership on Farm Bill